Neuronetics, Inc. (STIM) Stock Price & Analysis
Neuronetics, Inc. (STIM) rose 1.74% to USD 2.93 as of September 8, 2026 at 22:28 UTC, according to Nexqual real-time market data.
STIM last closed at USD 2.88; the session ranged USD 2.82–3 on volume of 1,419,451 shares. Market capitalization is $223.26M, with a 52-week range of USD 0.8–3.71 (NGM). Source: Nexqual, September 8, 2026 at 22:28 UTC.
Key Statistics (as of September 8, 2026 at 22:28 UTC)
| Price | USD 2.93 |
|---|---|
| Change | ▲ 1.74% (up) |
| Previous Close | USD 2.88 |
| Open | USD 2.85 |
| Day Range | USD 2.82 – 3 |
| 52-Week Range | USD 0.8 – 3.71 |
| Volume | 1,419,451 shares |
| Market Cap | $223.26M |
| Exchange | NGM |
Technical Analysis (STIM)
Nexqual's technical model rates STIM "BUY" based on 4 bullish and 1 bearish signals across 127 daily candles, as of September 8, 2026 at 22:28 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 58.4 (neutral) |
| vs SMA50 | Above (USD 2.3) |
| MACD | 0.14 (positive) |
Analyst Ratings (STIM)
Wall Street analysts rate STIM "None" based on 3 analysts, with a mean price target of USD 6 (range USD 5–7), per Nexqual as of September 8, 2026 at 22:28 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 6 |
| High Target | USD 7 |
| Low Target | USD 5 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (STIM)
| Next Earnings Date | 2026-11-03 |
|---|---|
| EPS Estimate | USD -0.11 |
| Revenue Estimate | $40.33M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.04 vs est -0.12 ▲ beat |
| 2026-03-31 | USD -0.15 vs est -0.17 ▲ beat |
| 2025-12-31 | USD -0.1 vs est -0.11 ▲ beat |
| 2025-09-30 | USD -0.13 vs est -0.12 ▼ miss |
Source: Nexqual, September 8, 2026 at 22:28 UTC.
Financials & Fundamentals (STIM)
| Total Revenue | $155.10M |
|---|---|
| Revenue Growth (YoY) | +9.10% |
| Gross Margin | +49.38% |
| Operating Margin | -3.61% |
| Profit Margin | -19.62% |
| ROE | -116.10% |
| Debt / Equity | 399.83 |
| Current Ratio | 1.88 |
| Total Cash | $19.20M |
| Total Debt | $86.52M |
| Free Cash Flow | $345,625 |
Source: Nexqual, September 8, 2026 at 22:28 UTC.
Financial Health Score (STIM)
Nexqual rates Neuronetics, Inc.'s overall financial health "Mixed" across five dimensions, as of September 8, 2026 at 22:28 UTC.
| Growth | Strong — Revenue +100% YoY (annual) |
|---|---|
| Profitability | Mixed — Gross margin 49%, operating -4% |
| Balance Sheet | Critical — $19M cash vs $87M debt |
| Cash Flow | Mixed — FCF $346K, slim 0.2% margin |
| Efficiency | Critical — ROE -116%, ROA -10.5% |
Ownership (STIM)
| Insider Ownership | +30.85% |
|---|---|
| Institutional Ownership | +54.01% |
| Shares Outstanding | 76.20M |
| Float | 37.15M |
| Short % of Float | +19.65% |
Source: Nexqual, September 8, 2026 at 22:28 UTC.
Leadership (STIM)
Neuronetics, Inc. is led by Daniel L. Reuvers (age 62), CEO, President & Director, per Nexqual as of September 8, 2026 at 22:28 UTC.
| CEO, President & Director | Daniel L. Reuvers (age 62) |
|---|---|
| Executive VP, CFO, Corporate Secretary, Principal Financial and Accounting Officer & Treasurer | Nir Naor C.F.A., CPA, L.L.M. (age 50) |
| Senior Vice President of Sales | Robert Greene |
| Executive Vice President & General Manager of Greenbrook | Cory S. Anderson (age 48) |
Major Backers & Investors (STIM)
Notable institutional backers of Neuronetics, Inc. include Madryn Asset Management, LP, UBS Group AG, Wexford Capital LP, according to Nexqual as of September 8, 2026 at 22:28 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Madryn Asset Management, LP | 24.33% |
| UBS Group AG | 2.99% |
| Wexford Capital LP | 2.63% |
| FourWorld Capital Management, LLC | 2.29% |
| Lane Generational LLC | 2.14% |
| Masters Capital Management, LLC | 1.31% |
| AdvisorShares Trust-AdvisorShares Psychedelics ETF | 1.08% |
| AdvisorShares Investments, LLC | 0.97% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 4.18% |
Source: Nexqual, September 8, 2026 at 22:28 UTC.
From Neuronetics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-17)
Key Strengths & Strategy (as disclosed to the SEC)
- Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally.
- The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.
- Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood.
- The company sells its products through its sales and customer support team to psychiatrists.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| VRCA | Verrica Pharmaceuticals Inc. | USD 5.26 | ▼ 1.87% |
| STRO | Sutro Biopharma, Inc. | USD 19.1 | ▼ 7.01% |
| SIBN | SI-BONE, Inc. | USD 18.62 | ▼ 0.11% |
| SYBX | Synlogic, Inc. | USD 1.23 | ▲ 0.82% |
| EVLO | Evelo Biosciences, Inc. | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 22:28 UTC. This page is informational and not investment advice.